Efficacy of Nintedanib in Idiopathic Pulmonary Fibrosis across Prespecified Subgroups in INPULSIS

被引:206
作者
Costabel, Ulrich [1 ]
Inoue, Yoshikazu [2 ]
Richeldi, Luca [3 ]
Collard, Harold R.
Tschoepe, Inga [4 ,5 ]
Stowasser, Susanne [6 ]
Azuma, Arata [7 ]
机构
[1] Univ Duisburg Essen, Univ Hosp, Ruhrlandklin, Essen, Germany
[2] Natl Hosp Org Kinki, Clin Res Ctr, Chuo Chest Med Ctr, Osaka, Japan
[3] Univ Southampton, Natl Inst Hlth Res, Southampton Resp Biomed Res Unit & Clin & Expt Sc, Southampton, Hants, England
[4] Univ Calif San Francisco, Dept Med, Div Pulm & Crit Care Med, San Francisco, CA USA
[5] Boehringer Ingelheim France SAS, Reims, France
[6] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany
[7] Nippon Med Sch, Grad Sch Med, Dept Pulm Med & Oncol, Tokyo 113, Japan
关键词
disease progression; forced vital capacity; quality of life; TYROSINE KINASE INHIBITOR; ACUTE EXACERBATION; PIRFENIDONE; DECLINE; TRIALS; FVC;
D O I
10.1164/rccm.201503-0562OC
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Rationale: In the two replicate, placebo-controlled, 52-week, phase III INPULSIS trials, nintedanib 150 mg twice daily significantly reduced the annual rate of decline in FVC, the primary endpoint, in subjects with idiopathic pulmonary fibrosis (IPF). It is unknown if this effect was uniform across all subjects treated with nintedanib. Objectives: To investigate the potential association of demographic and clinical variables with the effect of nintedanib in subjects with IPF. Methods: Subgroup analyses of pooled data from the INPULSIS trials were prespecified. Subgroups were analyzed by sex, age (<65, >= 65 yr), race (white, Asian), baseline FVC percentage predicted (<= 70%, >70%), baseline St. George's Respiratory Questionnaire (SGRQ) total score (<= 40, >40), smoking status (never, ex/current), systemic corticosteroid use (yes/no), and bronchodilator use (yes/no). Measurements and Main Results: A total of 1,061 subjects were treated (nintedanib n = 638, placebo n = 423). There was no statistically significant difference in the effect of nintedanib for the primary endpoint or the key secondary endpoints of change from baseline in SGRQ total score or time to first acute exacerbation in any subgroup. Treatment effects for the key secondary endpoints seemed more pronounced in subjects with baseline FVC <= 70% predicted, because the majority of acute exacerbations and a greater deterioration in SGRQ total score occurred in placebo-treated subjects in this subgroup. Conclusions: Pooled data from the INPULSIS trials support a consistent effect of nintedanib across a range of IPF phenotypes by slowing disease progression across a number of prespecified subgroups.
引用
收藏
页码:178 / 185
页数:8
相关论文
共 24 条
[1]   Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment [J].
Azuma, Arata ;
Taguchi, Yoshio ;
Ogura, Takashi ;
Ebina, Masahito ;
Taniguchi, Hiroyuki ;
Kondoh, Yasuhiro ;
Suga, Moritaka ;
Takahashi, Hiroki ;
Nakata, Koichiro ;
Sato, Atsuhiko ;
Kudoh, Shoji ;
Nukiwa, Toshihiro .
RESPIRATORY RESEARCH, 2011, 12
[2]  
Boehringer Ingelheim, 2015, OFEV NINT SUMM PROD
[3]  
Cattin V, 2014, INT C LUNG AIRW FIBR
[4]   Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials [J].
Collard, Harold R. ;
Yow, Eric ;
Richeldi, Luca ;
Anstrom, Kevin J. ;
Glazer, Craig .
RESPIRATORY RESEARCH, 2013, 14
[5]  
Costabel U, 2014, INT C LUNG AIRW FIBR
[6]  
Costabel U, 2014, EUR RESP J S58, V44, pA1907
[7]  
Elidel, 2014, LID PATCH 5 PRESCR I
[8]  
European Medicines Agency Committee for Medicinal Products for Human Use (CHMP), 2014, DRAFT GUID INV SUBGR
[9]   Gender influences health-related Quality of Life in IPF [J].
Han, MeiLan K. ;
Swigris, Jeffrey ;
Liu, Lyrica ;
Bartholmai, Brian ;
Murray, Susan ;
Giardino, Nicholas ;
Thompson, Bruce ;
Frederick, Margaret ;
Li, Daner ;
Schwarz, Marvin ;
Limper, Andrew ;
Flaherty, Kevin ;
Martinez, Fernando J. .
RESPIRATORY MEDICINE, 2010, 104 (05) :724-730
[10]   BIBF 1120: Triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy [J].
Hilberg, Frank ;
Roth, Gerald J. ;
Krssak, Martin ;
Kautschitsch, Susanna ;
Sommergruber, Wolfgang ;
Tontsch-Grunt, Ulrike ;
Garin-Chesa, Pilar ;
Bader, Gerd ;
Zoephel, Andreas ;
Quant, Jens ;
Heckel, Armin ;
Rettig, Wolfgang J. .
CANCER RESEARCH, 2008, 68 (12) :4774-4782